Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
September 25, 2024 07:00 ET
|
Kymera Therapeutics, Inc.
KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human...
Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021
September 25, 2024 03:00 ET
|
Medigene AG
Planegg/Martinsried, September 25, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern Time
September 23, 2024 19:10 ET
|
Regen BioPharma, Inc.
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO,...
Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024
September 14, 2024 07:30 ET
|
Medigene AG
Planegg/Martinsried, September 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
September 09, 2024 16:06 ET
|
Imunon, Inc.
September 18th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline ...
Medigene Announces U.S. FDA Clearance of IND Application for MDG1015, a First-in-Class, Third Generation T Cell Receptor Engineered T Cell (TCR-T) Therapy for Multiple Solid Tumor Indications
September 05, 2024 08:00 ET
|
Medigene AG
Planegg/Martinsried, September 5, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
EpimAb Biotherapeutics and Vignette Bio Announce Strategic Collaboration to Develop EMB-06, a BCMA×CD3 Bispecific Antibody
September 03, 2024 21:00 ET
|
Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI and SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, Inc. (“EpimAb” or “EpimAb Biotherapeutics”) a clinical stage biopharmaceutical company specializing in the...
Alumis to Participate in Upcoming September Investor Conferences
September 03, 2024 16:29 ET
|
Alumis Inc.
Alumis will be participating in several investor conferences in September
Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform
August 29, 2024 05:00 ET
|
Medigene AG
Planegg/Martinsried, August 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Immunology Market to Reach $204.0 Billion, Globally, by 2033 at 6.3% CAGR: Allied Market Research
August 28, 2024 06:40 ET
|
Allied Analytics LLP
Wilmington, Delaware, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Immunology Market by Product Type (Diagnostic Testing Equipment, Biomarkers and...